Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Sell
43
ALNY Quote, Financials, Valuation and Earnings
Last price:
$400.79
Seasonality move
:
2.83%
Day range:
$395.99 - $407.43
52-week range:
$205.87 - $495.55
Dividend yield:
0%
P/E ratio:
1,657.01x
P/S ratio:
16.35x
P/B ratio:
225.10x
Volume:
1.1M
Avg. volume:
1.5M
1-year change:
64.58%
Market cap:
$52.6B
Revenue:
$2.2B
EPS (TTM):
$0.24
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$974.1M | $1.75 | 98.51% | -58.59% | $491.92 |
|
BBIO
BridgeBio Pharma, Inc.
|
$106.1M | -$0.78 | 2431.54% | -55.45% | $85.78 |
|
BIIB
Biogen, Inc.
|
$2.3B | $3.88 | -5.31% | -3.31% | $180.69 |
|
GKOS
Glaukos Corp.
|
$122.5M | -$0.26 | 22.71% | -65.32% | $124.07 |
|
INSM
Insmed, Inc.
|
$115.5M | -$1.37 | 66.86% | -2.57% | $214.78 |
|
PFE
Pfizer Inc.
|
$16.5B | $0.63 | -4.58% | 694.41% | $28.62 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$398.51 | $491.92 | $52.6B | 1,657.01x | $0.00 | 0% | 16.35x |
|
BBIO
BridgeBio Pharma, Inc.
|
$76.45 | $85.78 | $14.7B | -- | $0.00 | 0% | 41.16x |
|
BIIB
Biogen, Inc.
|
$174.84 | $180.69 | $25.6B | 15.94x | $0.00 | 0% | 2.65x |
|
GKOS
Glaukos Corp.
|
$116.18 | $124.07 | $6.7B | -- | $0.00 | 0% | 14.02x |
|
INSM
Insmed, Inc.
|
$176.77 | $214.78 | $37.7B | -- | $0.00 | 0% | 75.23x |
|
PFE
Pfizer Inc.
|
$24.88 | $28.62 | $141.5B | 14.50x | $0.43 | 6.91% | 2.26x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
92.22% | 1.279 | 4.61% | 2.37x |
|
BBIO
BridgeBio Pharma, Inc.
|
350.59% | 0.711 | 27% | 3.52x |
|
BIIB
Biogen, Inc.
|
26.58% | 0.737 | 32.07% | 1.77x |
|
GKOS
Glaukos Corp.
|
11.94% | 1.326 | 2.23% | 4.35x |
|
INSM
Insmed, Inc.
|
44.07% | 2.512 | 2.43% | 4.18x |
|
PFE
Pfizer Inc.
|
39.94% | 0.301 | 42.51% | 0.81x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$1B | $368M | 1.51% | 31.15% | 29.46% | $313M |
|
BBIO
BridgeBio Pharma, Inc.
|
$113.4M | -$136.4M | -109.98% | -- | -112.97% | -$112.4M |
|
BIIB
Biogen, Inc.
|
$1.6B | $613.8M | 6.76% | 9.36% | 25% | $1.2B |
|
GKOS
Glaukos Corp.
|
$104.7M | -$16.4M | -10.16% | -11.73% | -12.26% | -$11.7M |
|
INSM
Insmed, Inc.
|
$111.4M | -$261.4M | -70.98% | -193.23% | -183.61% | -$222.2M |
|
PFE
Pfizer Inc.
|
$11.2B | $5.5B | 6.35% | 10.84% | 33.21% | $4B |
Alnylam Pharmaceuticals, Inc. vs. Competitors
-
Which has Higher Returns ALNY or BBIO?
BridgeBio Pharma, Inc. has a net margin of 20.1% compared to Alnylam Pharmaceuticals, Inc.'s net margin of -153.22%. Alnylam Pharmaceuticals, Inc.'s return on equity of 31.15% beat BridgeBio Pharma, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital ALNYAlnylam Pharmaceuticals, Inc.83.98% $1.84 $3B BBIOBridgeBio Pharma, Inc.93.98% -$0.95 $781.7M -
What do Analysts Say About ALNY or BBIO?
Alnylam Pharmaceuticals, Inc. has a consensus price target of $491.92, signalling upside risk potential of 20.65%. On the other hand BridgeBio Pharma, Inc. has an analysts' consensus of $85.78 which suggests that it could grow by 11.27%. Given that Alnylam Pharmaceuticals, Inc. has higher upside potential than BridgeBio Pharma, Inc., analysts believe Alnylam Pharmaceuticals, Inc. is more attractive than BridgeBio Pharma, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ALNYAlnylam Pharmaceuticals, Inc.14 7 0 BBIOBridgeBio Pharma, Inc.15 1 0 -
Is ALNY or BBIO More Risky?
Alnylam Pharmaceuticals, Inc. has a beta of 0.301, which suggesting that the stock is 69.879% less volatile than S&P 500. In comparison BridgeBio Pharma, Inc. has a beta of 1.256, suggesting its more volatile than the S&P 500 by 25.58%.
-
Which is a Better Dividend Stock ALNY or BBIO?
Alnylam Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BridgeBio Pharma, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Alnylam Pharmaceuticals, Inc. pays -- of its earnings as a dividend. BridgeBio Pharma, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ALNY or BBIO?
Alnylam Pharmaceuticals, Inc. quarterly revenues are $1.2B, which are larger than BridgeBio Pharma, Inc. quarterly revenues of $120.7M. Alnylam Pharmaceuticals, Inc.'s net income of $251.1M is higher than BridgeBio Pharma, Inc.'s net income of -$184.9M. Notably, Alnylam Pharmaceuticals, Inc.'s price-to-earnings ratio is 1,657.01x while BridgeBio Pharma, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alnylam Pharmaceuticals, Inc. is 16.35x versus 41.16x for BridgeBio Pharma, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ALNYAlnylam Pharmaceuticals, Inc.16.35x 1,657.01x $1.2B $251.1M BBIOBridgeBio Pharma, Inc.41.16x -- $120.7M -$184.9M
-
Which has Higher Returns ALNY or BIIB?
Biogen, Inc. has a net margin of 20.1% compared to Alnylam Pharmaceuticals, Inc.'s net margin of 19%. Alnylam Pharmaceuticals, Inc.'s return on equity of 31.15% beat Biogen, Inc.'s return on equity of 9.36%.
Company Gross Margin Earnings Per Share Invested Capital ALNYAlnylam Pharmaceuticals, Inc.83.98% $1.84 $3B BIIBBiogen, Inc.64.29% $3.17 $24.8B -
What do Analysts Say About ALNY or BIIB?
Alnylam Pharmaceuticals, Inc. has a consensus price target of $491.92, signalling upside risk potential of 20.65%. On the other hand Biogen, Inc. has an analysts' consensus of $180.69 which suggests that it could grow by 3.43%. Given that Alnylam Pharmaceuticals, Inc. has higher upside potential than Biogen, Inc., analysts believe Alnylam Pharmaceuticals, Inc. is more attractive than Biogen, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ALNYAlnylam Pharmaceuticals, Inc.14 7 0 BIIBBiogen, Inc.14 18 1 -
Is ALNY or BIIB More Risky?
Alnylam Pharmaceuticals, Inc. has a beta of 0.301, which suggesting that the stock is 69.879% less volatile than S&P 500. In comparison Biogen, Inc. has a beta of 0.128, suggesting its less volatile than the S&P 500 by 87.226%.
-
Which is a Better Dividend Stock ALNY or BIIB?
Alnylam Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biogen, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Alnylam Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Biogen, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ALNY or BIIB?
Alnylam Pharmaceuticals, Inc. quarterly revenues are $1.2B, which are smaller than Biogen, Inc. quarterly revenues of $2.5B. Alnylam Pharmaceuticals, Inc.'s net income of $251.1M is lower than Biogen, Inc.'s net income of $466.5M. Notably, Alnylam Pharmaceuticals, Inc.'s price-to-earnings ratio is 1,657.01x while Biogen, Inc.'s PE ratio is 15.94x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alnylam Pharmaceuticals, Inc. is 16.35x versus 2.65x for Biogen, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ALNYAlnylam Pharmaceuticals, Inc.16.35x 1,657.01x $1.2B $251.1M BIIBBiogen, Inc.2.65x 15.94x $2.5B $466.5M
-
Which has Higher Returns ALNY or GKOS?
Glaukos Corp. has a net margin of 20.1% compared to Alnylam Pharmaceuticals, Inc.'s net margin of -12.16%. Alnylam Pharmaceuticals, Inc.'s return on equity of 31.15% beat Glaukos Corp.'s return on equity of -11.73%.
Company Gross Margin Earnings Per Share Invested Capital ALNYAlnylam Pharmaceuticals, Inc.83.98% $1.84 $3B GKOSGlaukos Corp.78.41% -$0.28 $873.9M -
What do Analysts Say About ALNY or GKOS?
Alnylam Pharmaceuticals, Inc. has a consensus price target of $491.92, signalling upside risk potential of 20.65%. On the other hand Glaukos Corp. has an analysts' consensus of $124.07 which suggests that it could grow by 6.79%. Given that Alnylam Pharmaceuticals, Inc. has higher upside potential than Glaukos Corp., analysts believe Alnylam Pharmaceuticals, Inc. is more attractive than Glaukos Corp..
Company Buy Ratings Hold Ratings Sell Ratings ALNYAlnylam Pharmaceuticals, Inc.14 7 0 GKOSGlaukos Corp.11 0 1 -
Is ALNY or GKOS More Risky?
Alnylam Pharmaceuticals, Inc. has a beta of 0.301, which suggesting that the stock is 69.879% less volatile than S&P 500. In comparison Glaukos Corp. has a beta of 0.692, suggesting its less volatile than the S&P 500 by 30.762%.
-
Which is a Better Dividend Stock ALNY or GKOS?
Alnylam Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Glaukos Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Alnylam Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Glaukos Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ALNY or GKOS?
Alnylam Pharmaceuticals, Inc. quarterly revenues are $1.2B, which are larger than Glaukos Corp. quarterly revenues of $133.5M. Alnylam Pharmaceuticals, Inc.'s net income of $251.1M is higher than Glaukos Corp.'s net income of -$16.2M. Notably, Alnylam Pharmaceuticals, Inc.'s price-to-earnings ratio is 1,657.01x while Glaukos Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alnylam Pharmaceuticals, Inc. is 16.35x versus 14.02x for Glaukos Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ALNYAlnylam Pharmaceuticals, Inc.16.35x 1,657.01x $1.2B $251.1M GKOSGlaukos Corp.14.02x -- $133.5M -$16.2M
-
Which has Higher Returns ALNY or INSM?
Insmed, Inc. has a net margin of 20.1% compared to Alnylam Pharmaceuticals, Inc.'s net margin of -259.95%. Alnylam Pharmaceuticals, Inc.'s return on equity of 31.15% beat Insmed, Inc.'s return on equity of -193.23%.
Company Gross Margin Earnings Per Share Invested Capital ALNYAlnylam Pharmaceuticals, Inc.83.98% $1.84 $3B INSMInsmed, Inc.78.29% -$1.75 $1.7B -
What do Analysts Say About ALNY or INSM?
Alnylam Pharmaceuticals, Inc. has a consensus price target of $491.92, signalling upside risk potential of 20.65%. On the other hand Insmed, Inc. has an analysts' consensus of $214.78 which suggests that it could grow by 21.6%. Given that Insmed, Inc. has higher upside potential than Alnylam Pharmaceuticals, Inc., analysts believe Insmed, Inc. is more attractive than Alnylam Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ALNYAlnylam Pharmaceuticals, Inc.14 7 0 INSMInsmed, Inc.17 1 0 -
Is ALNY or INSM More Risky?
Alnylam Pharmaceuticals, Inc. has a beta of 0.301, which suggesting that the stock is 69.879% less volatile than S&P 500. In comparison Insmed, Inc. has a beta of 1.015, suggesting its more volatile than the S&P 500 by 1.49%.
-
Which is a Better Dividend Stock ALNY or INSM?
Alnylam Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insmed, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Alnylam Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Insmed, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ALNY or INSM?
Alnylam Pharmaceuticals, Inc. quarterly revenues are $1.2B, which are larger than Insmed, Inc. quarterly revenues of $142.3M. Alnylam Pharmaceuticals, Inc.'s net income of $251.1M is higher than Insmed, Inc.'s net income of -$370M. Notably, Alnylam Pharmaceuticals, Inc.'s price-to-earnings ratio is 1,657.01x while Insmed, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alnylam Pharmaceuticals, Inc. is 16.35x versus 75.23x for Insmed, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ALNYAlnylam Pharmaceuticals, Inc.16.35x 1,657.01x $1.2B $251.1M INSMInsmed, Inc.75.23x -- $142.3M -$370M
-
Which has Higher Returns ALNY or PFE?
Pfizer Inc. has a net margin of 20.1% compared to Alnylam Pharmaceuticals, Inc.'s net margin of 21.32%. Alnylam Pharmaceuticals, Inc.'s return on equity of 31.15% beat Pfizer Inc.'s return on equity of 10.84%.
Company Gross Margin Earnings Per Share Invested Capital ALNYAlnylam Pharmaceuticals, Inc.83.98% $1.84 $3B PFEPfizer Inc.67.15% $0.62 $154.8B -
What do Analysts Say About ALNY or PFE?
Alnylam Pharmaceuticals, Inc. has a consensus price target of $491.92, signalling upside risk potential of 20.65%. On the other hand Pfizer Inc. has an analysts' consensus of $28.62 which suggests that it could grow by 15.04%. Given that Alnylam Pharmaceuticals, Inc. has higher upside potential than Pfizer Inc., analysts believe Alnylam Pharmaceuticals, Inc. is more attractive than Pfizer Inc..
Company Buy Ratings Hold Ratings Sell Ratings ALNYAlnylam Pharmaceuticals, Inc.14 7 0 PFEPfizer Inc.7 15 1 -
Is ALNY or PFE More Risky?
Alnylam Pharmaceuticals, Inc. has a beta of 0.301, which suggesting that the stock is 69.879% less volatile than S&P 500. In comparison Pfizer Inc. has a beta of 0.457, suggesting its less volatile than the S&P 500 by 54.271%.
-
Which is a Better Dividend Stock ALNY or PFE?
Alnylam Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer Inc. offers a yield of 6.91% to investors and pays a quarterly dividend of $0.43 per share. Alnylam Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Pfizer Inc. pays out 119.94% of its earnings as a dividend.
-
Which has Better Financial Ratios ALNY or PFE?
Alnylam Pharmaceuticals, Inc. quarterly revenues are $1.2B, which are smaller than Pfizer Inc. quarterly revenues of $16.7B. Alnylam Pharmaceuticals, Inc.'s net income of $251.1M is lower than Pfizer Inc.'s net income of $3.6B. Notably, Alnylam Pharmaceuticals, Inc.'s price-to-earnings ratio is 1,657.01x while Pfizer Inc.'s PE ratio is 14.50x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alnylam Pharmaceuticals, Inc. is 16.35x versus 2.26x for Pfizer Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ALNYAlnylam Pharmaceuticals, Inc.16.35x 1,657.01x $1.2B $251.1M PFEPfizer Inc.2.26x 14.50x $16.7B $3.6B
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 36x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
60
AAOI alert for Dec 24
Applied Optoelectronics, Inc. [AAOI] is up 5.1% over the past day.
Buy
85
HUT alert for Dec 24
Hut 8 Corp. [HUT] is up 0.65% over the past day.
Buy
63
GPCR alert for Dec 24
Structure Therapeutics, Inc. [GPCR] is down 2.36% over the past day.
